REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Result of Annual General Meeting

MaxCyteAnnouncement

19/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250619:nRSS5470Na&default-theme=true

RNS Number : 5470N  MaxCyte, Inc.  19 June 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF
DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS
ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MaxCyte Inc.

("MaxCyte" or the "Company")

Result of Annual General Meeting

 

ROCKVILLE, Md., LONDON, UK, 19 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell therapeutics today announces that at its Annual General
Meeting held yesterday, all resolutions were duly passed.

The full text of the resolutions proposed and passed at the Annual General
Meeting can be found in the proxy statement which was published and posted to
stockholders on April 28, 2025 and copies of which are available in the
SEC's EDGAR filing database on the SEC's website at www.sec.gov
(https://protect.checkpoint.com/v2/___http:/www.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo1ZTViNDFkOTgxMmFkMzY5ZGViMDI5OTAyZDY4YzVmNDo2OmJhMmU6ZjBjOGE5Zjc4YWM3ZGI3ZmU0YWI2ZjJlNzVhYmIwZThjOWQ4MjNmZTRlODlmYWIxZjI0ZmU3ZjRiNzZiNjYwZTpwOlQ6Rg)
.

AIM Delisting

Among the resolutions passed by stockholders was a resolution for the
cancellation of the admission of the Company's Common Stock to trading on AIM.
Accordingly, it is expected that the last day of dealings in the Company's
Common Stock on AIM will be 25 June 2025 and that the cancellation of their
admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June
2025.

Following the delisting, there will be no public market in the United Kingdom
on which the Common Stock can be traded, however the Company will retain
its U.S. listing of Common Stock on the Nasdaq Global Select Market
("Nasdaq") under ticker symbol MXCT.

Further information regarding the delisting, including arrangements for how
investors can continue to trade the Company's Common Stock on Nasdaq and other
'frequently asked questions', can be found at:
https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a
(https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a)

Maher Masoud, President and CEO of MaxCyte commented: "I would like to thank
our shareholders for their support since the Company's AIM listing in 2016.
The belief and continued commitment from our U.K. investors in our vision of
enabling cell and gene therapies allowed us to have the foundation to become
the only cell-engineering technology used in the engineering of a commercial
non-viral gene edited product. While we will be a Nasdaq only listed company,
all of our shareholders have my commitment to our continued engagement. Cell
and gene therapies are the future of medicine, and with the continued support
from our shareholders, MaxCyte's leading non-viral cell-engineering platform
with SeQure's DX's gene editing risk assessment services will help drive
precision medicine forward."

For further information, please contact:

 

   MaxCyte Contacts:

   US IR Adviser                                 +1 415-937-5400

   Gilmartin Group                               ir@maxcyte.com

   David Deuchler, CFA

   Nominated Adviser and Joint Corporate Broker

   Panmure Liberum                               +44 (0)20 7886 2500

   Emma Earl / Mark Rogers

   Corporate Broking

   Rupert Dearden

   UK IR Adviser                                 +44 (0)203 709 5700

   ICR Healthcare                                maxcyte@icrhealthcare.com

   Mary-Jane Elliott

   Chris Welsh

 

Additional Information

The person responsible for arranging the release of this information on behalf
of the Company is David Sandoval, General Counsel.

 

About MaxCyte

At MaxCyte(®), we are committed to building better cells together. As a
leading cell-engineering company, we are driving the discovery, development
and commercialization of next-generation cell therapies. Our best-in-class
Flow Electroporation(®) technology and SeQure DX™ gene editing risk
assessment services enable precise, efficient and scalable cell engineering.
Supported by expert scientific, technical and regulatory guidance, our
platform empowers researchers from around the world to engineer diverse cell
types and payloads, accelerating the development of safe and effective
treatments for human health. For more than 25 years, we've been advancing cell
engineering, shaping the future of medicine. Learn more at maxcyte.com
(https://www.globenewswire.com/Tracker?data=f7MZAm2OsUduwxl6CYAmgoKCIwuYkIpwN743nOeFpfmoPR6FlUlBKF0ZGi05jNB7Quo4OaRNy6-wB8Bmz3t0g5An8O856Cvhpo2-lTGLir6xz5Qv05BrIhxU0P2cv2fVS9v8mjQflKTdySxyK_ACrj9zVEEiPAng9ac3AXqjttnVG9TQ4JjcpvQLuCho8U-APV7NFdO5-8tE3CwW582nuGsj7IO01TIFSuOfQej1dcxGF-phV0fpqoojJi5rpGzF2BaQT5X8ickxDTxEGeHb-99GJ96MnnY1LZZUGHl07FPGbt-if015P2rKdy2llQRgukpvX_wiHw44KbiBVjjg0Oewa1gsjlHjSvP7piyIblZ8fP1ny_7F8FOg79eqI5-8)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=rjuRjaZHpEXzNljmpsgvNWQpu2NKxGiErlhs4csnoJ4LVC_R6EOOAlsgidOHGozxdXLhsj6Z1W7nLswWB1Z1MmaG1tbqOIdTaSS3_ARw8gLjlJb2Ow5_pMyYhwMlDlNkRe1hYqiW2TKuUwL1oIEoLfGNB7BjvVSN8irQpxq-oJypHQ6IDcBNPpVNkYIy4YdLyz_UeBiyw8tUFVJ0iQNFJsGRGIPFfIy9qf0LyAmEgaLi73dMaItKZAvb41MRnVwRl8xUzRWW_EQkCTK7qgWmjatusSKXx4VkYn80WX4JUEyK13JFiGqTv2uYxmHROZvcsKAONecH1cg7kR4Eg5m86CyfRGWfa6eSPCWzVlJznDfRbk2DMo8pCyIEZ49-dSjf)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=vcNmZbomBnBvgZ7X0zu3oYyECP-sTjHMbgigqrWax_SW6J6f63Vz3B0S2bQmloni5Rg1Twb9HS-4XqRKgZ3NtMDRpnxDtPc-_C2CO08P-BBdyyGetjYjwPWjlrlz4jE2hyvKC0j99b9zsj6n8eWbTw==)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGUGDLUXBDGUC